|
1
|
Aggarwal BB, Bhardwaj A, Aggarwal RS,
Seeram NP, Shishodia S and Takada Y: Role of resveratrol in
prevention and therapy of cancer: preclinical and clinical studies.
Anticancer Res. 24:2783–2840. 2004.
|
|
2
|
Jang M, Cai L, Udeani GO, Slowing KV,
Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta
RG, Moon RC and Pezzuto JM: Cancer chemopreventive activity of
resveratrol, a natural product derived from grapes. Science.
275:218–220. 1997.
|
|
3
|
Banerjee S, Bueso-Ramos C and Aggarwal BB:
Suppression of 7,12- dimethylbenz(a)anthracene-induced mammary
carcinogenesis in rats by resveratrol: role of nuclear factor-κB,
cyclooxygenase 2, and matrix metalloproteinase 9. Cancer Res.
62:4945–4954. 2002.
|
|
4
|
Li ZG, Hong T, Shimada Y, Komoto I, Kawabe
A, Ding Y, Kaganoi J, Hashimoto Y and Imamura M: Suppression of
N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis
in F344 rats by resveratrol. Carcinogenesis. 23:1531–1536.
2002.
|
|
5
|
Lee EO, Lee HJ, Hwang HS, Ahn KS, Chae C,
Kang KS, Lu J and Kim SH: Potent inhibition of Lewis lung cancer
growth by heyneanol A from the roots of Vitis amurensis through
apoptotic and anti-angiogenic activities. Carcinogenesis.
27:2059–2069. 2006.
|
|
6
|
Liu HS, Pan CE, Yang W and Liu XM:
Antitumor and immunomodulatory activity of resveratrol on
experimentally implanted tumor of H22 in Balb/c mice. World J
Gastroenterol. 9:1474–1476. 2003.
|
|
7
|
Tessitore L, Davit A, Sarotto I and
Caderni G: Resveratrol depresses the growth of colorectal aberrant
crypt foci by affecting bax and p21(CIP) expression.
Carcinogenesis. 21:1619–1622. 2000.
|
|
8
|
Chen Y, Tseng S-H, Lai H-S and Chen W-J:
Resveratrol-induced cellular apoptosis and cell cycle arrest in
neuroblastoma cells and antitumor effects on neuroblastoma in mice.
Surgery. 136:57–66. 2004.
|
|
9
|
Colin D, Limagne E, Jeanningros S, Jacquel
A, Lizard G, Athias A, Gambert P, Hichami A, Latruffe N, Solary E
and Delmas D: Endocytosis of resveratrol via lipid rafts and
activation of downstream signaling pathways in cancer cells. Cancer
Prev Res. 4:1095–1106. 2011.
|
|
10
|
Li G, He S, Chang L, Lu H, Zhang H and
Chiu J: GADD45α and annexin A1 are involved in the apoptosis of
HL-60 induced by resveratrol. Phytomedicine. 18:704–709. 2011.
|
|
11
|
Kartal M, Saydam G, Sahin F and Baran Y:
Resveratrol triggers apoptosis through ceramide metabolizing genes
in human K562 chronic myeloid leukemia cells. Nutr Cancer.
63:637–644. 2011.
|
|
12
|
Faderl S, Kantarjian HM, Talpaz M and
Estrov Z: Clinical significance of cytogenetic abnormalities in
adult acute lymphoblastic leukemia. Blood. 91:3995–4019. 1998.
|
|
13
|
Greaves MF and Wiemels J: Origins of
chromosome translocations in childhood leukaemia. Nat Rev. 3:1–11.
2003.
|
|
14
|
Greil J, Gramatzki M, Burger R, Marschalek
R, Peltner M, Trautmann U, Hansen-Hagge TE, Bartram CR, Fey GH,
Stehr K and Beck J: The acute lymphoblastic leukaemia cell line SEM
with t(4;11) chromosomal rearrangement is biphenotypic and
responsive to interleukin-7. Br J Hemotol. 86:275–283. 1994.
|
|
15
|
Stong RC, Korsmeyer SJ, Parkin JL, Arthur
DC and Kersey JH: Human acute leukemia cell line with the t(4;11)
chromosomal rearrangement exhibits B lineage and monocytic
characteristics. Blood. 65:21–31. 1985.
|
|
16
|
Lange B, Valtieri M, Santoli D, Caracciolo
D, Mavilio F, Gemperlein I, Griffin C, Emanuel B, Finan J and
Nowell P: Growth factor requirements of childhood acute leukemia:
establishment of GM-CSF-dependent cell lines. Blood. 70:192–199.
1987.
|
|
17
|
Lock RB, Liem N, Farnsworth ML, Milross
CG, Xue C, Tajbakhsh M, Haber M, Norris MD, Marshall GM and Rice
AM: The nonobese diabetic/severe combined immunodeficient
(NOD/SCID) mouse model of childhood acute lymphoblastic leukemia
reveals intrinsic differences in biologic characteristics at
diagnosis and relapse. Blood. 99:4100–4108. 2002.
|
|
18
|
Liem NLM, Papa RA, Milross CG, Schmid MA,
Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD,
MacKenzie KL and Lock RB: Characterization of childhood acute
lymphoblastic leukemia xenograft models for the preclinical
evaluation of new therapies. Blood. 103:3905–3914. 2004.
|
|
19
|
Shultz LD, Ishikawa F and Greiner DL:
Humanized mice in translational biomedical research. Nat Rev
Immunol. 7:118–130. 2007.
|
|
20
|
Lee EM, Bachman PS and Lock RB: Xenograft
models for the preclinical evaluation of new therapies in acute
leukemia. Leuk Lymphoma. 48:659–668. 2007.
|
|
21
|
Borgmann A, Baldy C, von Stackelberg A,
Beyermann B, Fichtner I, Nurnberg P and Henze G: Childhood ALL
blasts retain phenotypic and genotypic characteristics upon
long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol.
17:635–650. 2000.
|
|
22
|
Dörrie J, Gerauer H, Wachter Y and Zunino
SJ: Resveratrol induces extensive apoptosis by depolarizing
mitochondrial membranes and activating caspase-9 in acute
lymphoblastic leukemia cells. Cancer Res. 61:4731–4739. 2001.
|
|
23
|
Nachman JB, Sather HN, Sensel MG, Trigg
ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM and Gaynon PS:
Augmented post-induction therapy for children with high-risk acute
lymphoblastic leukemia and a slow response to initial therapy. N
Engl J Med. 338:1663–1671. 1998.
|
|
24
|
Center for Veterinary Medicine, Food and
Drug Administration. Guidance for industry validation of analytical
procedures for type C medicated feeds #135. United States
Department of Health and Human Services; pp. 1–14. 2005, http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm052530.pdf.
|
|
25
|
Zunino SJ, Storms DH and Ducore JM: Novel
in vivo model of inducible multi-drug resistance in acute
lymphoblastic leukemia with chromosomal translocation t(4;11).
Cancer Lett. 296:49–54. 2010.
|
|
26
|
Lee M-H, Choi BY, Kundu JK, Shin YK, Na
H-K and Surh Y-J: Resveratrol suppresses growth of human ovarian
cancer cells in culture and in a murine xenograft model: eukaryotic
elongation factor 1A2 as a potential target. Cancer Res.
69:7449–7458. 2009.
|
|
27
|
Bai Y, Mao Q-Q, Qin J, Zheng X-Y, Wang
Y-B, Yang K, Shen H-F and Xie L-P: Resveratrol induces apoptosis
and cell cycle arrest of human T24 bladder cancer cells in vitro
and inhibits tumor growth in vivo. Cancer Sci. 101:488–493.
2010.
|
|
28
|
El-Mowafy AM, El-Mesery ME, Salem HA,
Al-Gayyar MM and Darweish MM: Prominent chemopreventive and
chemoenhancing effects for resveratrol: unraveling molecular
targets and the role of C-reactive protein. Chemotherapy. 56:60–65.
2010.
|
|
29
|
Kenealey JD, Subramanian L, Van Ginkel PR,
Darjatmoko S, Lindstrom MJ, Somoza V, Ghosh SK, Song Z, Hsung RP,
Kwon GS, Eliceiri KW, Albert DM and Polans AS: Resveratrol
metabolites do not elicit early pro-apoptotic mechanisms in
neuroblastoma cells. J Agric Food Chem. 59:4979–4986. 2011.
|
|
30
|
Lanzkowsky P, Shende A, Aral I and Saluja
G: Organ irradiation and combination chemotherapy in treatment of
acute lymphocytic leukaemia in children. Arch Dis Child.
50:685–690. 1975.
|
|
31
|
Crowell JA, Korytko PJ, Morrissey RL,
Booth TD and Levine BS: Resveratrol-associated renal toxicity.
Toxicol Sci. 82:614–619. 2004.
|
|
32
|
Vitrac X, Desmouliere A, Brouillaud B,
Krisa S, Deffieux G, Barthe N, Rosenbaum J and Merillon J-M:
Distribution of [14C]-trans-resveratrol, a cancer chemopreventive
polyphenol, in mouse tissues after oral administration. Life Sci.
72:2219–2233. 2003.
|
|
33
|
Yu C, Shin YG, Chow A, Li Y, Kosmeder JW,
Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG and van Breeman RB:
Human, rat, and mouse metabolism of resveratrol. Pharm Res.
19:1907–1914. 2002.
|
|
34
|
Wang Q, Xu J, Rottinghaus GE, Simonyi A,
Lubahn D, Sun GY and Sun AY: Resveratrol protects against global
cerebral ischemic injury in gerbils. Brain Res. 958:439–447.
2002.
|
|
35
|
Calamini B, Ratia K, Malkowski MG, Cuendet
M, Pezzuto JM, Santarsiero BD and Mesecar AD: Pleiotropic
mechanisms facilitated by resveratrol and its metabolites. Biochem
J. 429:273–282. 2010.
|
|
36
|
Hoshino J, Park E-J, Kondratyuk TP, Marler
L, Pezzuto JM, van Breemen RB, Mo S, Li Y and Cushman M: Selective
synthesis and biological evaluation of sulfate-conjugated
resveratrol metabolites. J Med Chem. 53:5033–5043. 2010.
|
|
37
|
Mikulski D and Molski M: Quantitative
structure-antioxidant activity relationship of trans-resveratrol
oligomers, trans-4,40-dihydroxystilbene dimer,
trans-resveratrol-3-O-glucuronide, glucosides: trans-piceid,
cis-piceid, trans-astringin and
trans-resveratrol-40-O-b-D-glucopyranoside. Eur J Med Chem.
45:2366–2380. 2010.
|
|
38
|
Miksits M, Wlcek K, Svoboda M, Kunert O,
Haslinger E, Thalhammer T, Szekeres T and Jäger W: Antitumor
activity of resveratrol and its sulfated metabolites against human
breast cancer cells. Planta Med. 75:1227–1230. 2009.
|
|
39
|
Soto BL, Hank JA, Darjatmoko SR, Polans
AS, Yanke EM, Rakhmilevich AL, Seo S, Kim K, Reisfeld RA, Gillies
SD and Sondel PM: Anti-tumor and immunomodulatory activity of
resveratrol in vitro and its potential for combining with cancer
immunotherapy. Int Immunopharmacol. 11:1877–1886. 2011.
|
|
40
|
Niu XF, Liu BQ, Du ZX, Gao YY, Li C, Li N,
Guan Y and Wang HQ: Resveratrol protects leukemic cells against
cytotoxicity induced by proteasome inhibitors via induction of
FOXO1 and p27Kip1. BMC Cancer. 11:992011.open access. [21418583]
|
|
41
|
Fukui M, Yamabe N and Zhu BT: Resveratrol
attenuates the anticancer efficacy of paclitaxel in human breast
cancer cells in vitro and in vivo. Eur J Cancer. 46:1882–1891.
2010.
|
